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Objective: Pulmonary embolism (PE) is the leading cause of maternal death in developed countries, and
the prevention of venous thromboembolism (VTE) is a pivotal part of current obstetric care. This study
evaluated the safety and efﬁcacy of enoxaparin sodium for thromboprophylaxis after cesarean section (C/
S), and analyzed the risk factors associated with VTE.
Materials and methods: One hundred and forty-three women deemed to be at high risk of postoperative
deep vein thrombosis (DVT) were enrolled between January 2011 and May 2012 in seven institutions in
Japan. Subcutaneous administration of enoxaparin 4000 units/d was initiated 24e36 hours after C/S for 5
days. Adverse events, based on the Common Terminology Criteria for Adverse Events, Version 4, were
recorded. The diagnoses of PE and DVT were made on clinical signs. Venous ultrasonography in the lower
extremities was performed in 102 patients. The association between VTE and various risk factors was
evaluated using univariate analysis.
Results: There were 10 (7.0%) Grade 1 adverse events: elevated aspartate aminotransferase or alanine
aminotransferase levels in eight patients, chest pain in one patient, and subcutaneous hematoma in one
patient. No patients showed clinical signs of PE and/or DVT. Among 102 patients who underwent venous
ultrasonography, thrombus was detected in unilateral soleus veins in four (3.9%) patients. A body mass
index (BMI)  25 kg/m2 before pregnancy was associated with asymptomatic DVT.
Conclusion: The current study demonstrates the safety and efﬁcacy of enoxaparin for thromboprophy-
laxis after C/S. Further studies are required to determine the best method of preventing asymptomatic
DVT.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Pulmonary thromboembolism (PTE) is the leading cause of
maternal death in Japan and the developed world [1e3]. Deep veintal, and Neonatal Medicine,
nan-ku, Fukuoka, 814e0180,
oshizato).
bstetrics & Gynecology. Publishedthrombosis (DVT), a major risk factor for PTE, may develop during
pregnancy and puerperium, especially after cesarean section (C/S)
[1e8]. The incidence of PTE after C/S is 0.06% and that of DVT after
C/S is 0.04% among the general population in Japan. After C/S,
women are estimated to have 22- and ﬁve-times higher risks of PTE
and DVT, respectively, than those after transvaginal delivery [2].
The rate of C/S has been increasing steadily over the past decades in
developed countries, including Japan [2]. Consequently, prevention
of venous thromboembolism (VTE) after C/S has become a pivotalby Elsevier Taiwan LLC. All rights reserved.
Table 1
Inclusion and exclusion criteria.
Inclusion criteria
Participants met all criteria listed below:
Written consent to participate in the study
Maternal age  20 y
Body weight  40 kg
Normal complete blood count & vital organ function, including the following:
(1) White blood cell count  4000/mm3
(2) Neutrophil count  2000/mm3
(3) Platelet count  100,000/mm3
(4) Hemoglobin concentrations  8 g/dL
Fig. 1. Study participants. BMI ¼ body mass index.
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incidence of maternal pregnancy-related death.
Low-molecular-weight heparin (LMWH) is widely used as an
agent for prevention of VTE after C/S in patients with risk factors,
such as thrombophilia or being overweight [4,5]. Many in-
vestigators have reported that LMWH is a safe means of providing
thromboprophylaxis after C/S [8e12]. Enoxaparin sodiumwas only
recently granted a license in Japan for thromboprophylaxis and
there have been few evaluations of its safety in pregnant Japanese
women [11]. The efﬁcacy of enoxaparin sodium has been estab-
lished in a series of studies that used the clinical signs of VTE after
major surgery [10,13,14]. However, the incidence of asymptomatic
DVT and its risk factors have not yet been studied in women
receiving thromboprophylaxis with enoxaparin sodium after C/S.
This study aims to establish the safety and efﬁcacy of enoxaparin
sodium for thromboprophylaxis after C/S inwomen at a known risk
of developing VTE based on clinical and laboratory signs. The efﬁ-
cacy of enoxaparin sodium by detection of asymptomatic DVT using
venous ultrasonography is evaluated. The risk factors associated
with VTE, including asymptomatic DVT in Japanese women un-
dergoing C/S were determined.(5) Serum aspartate aminotransferase & alanine aminotransferase
concentrations < 2.5 times the in-house normal value
(6) Total bilirubin concentrations  2.0 mg/dL
(7) Creatinine clearance  70 ml/min
(8) Peripheral oxygen saturation  90%
Participants met at least one of the criteria listed below:
History of venous thromboembolism
Presence or suspicion of thromboembolism
Family history of thromboembolism
Advanced maternal age ( 35 y)
Body mass index  25 kg/m2 before pregnancy
Bed rest for  48 hours before cesarean section (e.g., for threatened
preterm delivery, placenta previa)
Twin pregnancy
Hypertensive disorders of pregnancy (preeclampsia, chronic hypertension,
preeclampsia on chronic hypertension, & gestational hypertension) with
systolic blood pressure  160 &/or diastolic blood pressure  110 mmHg)
Marked varices in the lower extremities
Paralysis of the lower extremities
Exclusion criteria
History of allergy to heparin or heparin derivatives
History of heparin-induced thrombocytopenia
History of cerebral hemorrhage
Liver dysfunction (ChildePugh classiﬁcation > Grade A)
Clinical signs of bacterial endocarditis
Clinical signs of venous thromboembolism
Hemorrhage (intra-abdominal, retroperitoneal, intracranial, or in other vital
organs)Materials and methods
Study population
Participants included 151 Japanese women who fulﬁlled the
inclusion criteria (i.e., were considered to be at high risk of DVT),
but did not meet an exclusion criterion (Table 1) in seven in-
stitutions in Japan (Iizuka Hospital, Fukuoka University Hospital,
Yamaguchi Red Cross Hospital, Kitakyushu Municipal Hospital,
National Kyushu Medical Center, Kyushu Kosei Nenkin Hospital,
and Oita Prefectural Hospital). The study protocol was approved by
the Institutional Review Boards of all hospitals and written consent
was obtained from all participants. Patients were recruited at
34e36 weeks' gestation between January 2011 and May 2012. After
excluding one patient inwhom preexisting DVTwas diagnosed, 150
patients were enrolled in this study. Seven patients were further
excluded, including one who delivered transvaginally and six who
were anemic (serum hemoglobin concentration < 8 g/dL after C/S).
The remaining 143 patients were analyzed for evaluation of the
safety and efﬁcacy of enoxaparin sodium based on clinical and
laboratory signs (Fig. 1). For evaluation of asymptomatic DVT, 102
out of 143 participants were examined in three hospitals wherevenous ultrasonography of the lower extremities was available. In
the 143 participants, the median maternal age was 36.0 years
(range 22e49 years) and 53 womenwere primiparous. The median
gestational age at C/S was 38 weeks (range, 34e41 weeks) and 46
patients had emergency C/S performed. The indications for C/S
were previous C/S (n ¼ 52), twin pregnancy (n ¼ 39), malpre-
sentation (n ¼ 12), deterioration of preeclampsia (n ¼ 10), non-
reassuring fetal status (n ¼ 9), placenta previa (n ¼ 7), arrest of
labor (n ¼ 5), myomectomy before pregnancy (n ¼ 4), the presence
of myoma uteri causing cephalopelvic disproportion (n ¼ 4), and
obesity (n¼ 1). The indications for enoxaparin administrationwere
as follows: overweight, deﬁned as a BMI 25 kg/m2 before preg-
nancy (n ¼ 83); maternal age  35 years (n ¼ 81); bed rest
for  48 hours before C/S (e.g., because of threatened preterm
delivery or placenta previa) (n ¼ 54); twin pregnancy (n ¼ 41); and
hypertensive disorders of pregnancywith systolic blood pressure of
160 mmHg and/or diastolic blood pressure of 110 mmHg,
including preeclampsia, chronic hypertension, preeclampsia
superimposed on chronic hypertension, and gestational hyperten-
sion (n ¼ 28). The total number of indications is greater than the
number in the cohort because some women had more than one
indication.Study protocol
A total of 4000 units of enoxaparin sodium were administered
subcutaneously 24e36 hours after C/S, twice daily for 4 further
days, and once on the 6th postoperative day (Fig. 2). In 133 patients
in whom a continuous epidural infusion had been used for
Fig. 2. Study protocol. a Venus ultrasound (U/S) examinations were undertaken in 102 cases. b If epidural anesthesia had been used for perioperative pain control. C/S ¼ cesarean
section.
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or 2 hours after the administration of enoxaparin sodium. In all
patients, additional prophylactic measures to prevent DVT,
including compression stockings and/or intermittent compression
of the lower extremities during and after C/S, were used. Venous
blood specimens were obtained for complete blood count, serum
biochemistry, and coagulation assays. A physical examination was
undertaken to detect DVT and pulmonary embolism (PE). Periph-
eral oxygen saturation (SpO2) was measured on postoperative Day
1 (before the administration of enoxaparin sodium) and on Day 3
and Day 6. Venous ultrasonography of the lower extremities,
including the calf veins, was examined in 102 of the 143 partici-
pants at 34e36 weeks' gestation and at 6 days after C/S by expe-
rienced sonographers according to a standard protocol [15].
Parameters for evaluation of safety and efﬁcacy of enoxaparin
sodium
Adverse events were evaluated based on the Common Termi-
nology Criteria for Adverse Events, Version 4. The efﬁcacy of
enoxaparin sodium for prevention of DVT was assessed by clinical
examination or venous sonography, and for prevention of PE, by
clinical examination. Univariate analysis was used to assess risk
factors in women who were diagnosed with venous thrombosis.
Statistical analysis
Statistical analyses were performed using the ManneWhitney U
test and Chi-square test for assessment of risk factors associated
with VTE. IBM SPSS statistics (Version 22; IBM, Armonk, NY, USA)
was used for analysis. Statistical signiﬁcance was deﬁned as
p < 0.05.
Results
Ten women in the cohort of 143 (7.0%) experienced Grade 1
adverse events as follows: elevated aspartate aminotransferase or
alanine aminotransferase levels greater than the upper limit of
normal and less than three times the upper limit of normal in eight
patients; chest pain (i.e., mild pain) in one patient, and subcu-
taneous hemorrhage (i.e., minimal bleeding was identiﬁed on
clinical examination; intervention not indicated) in one patient. No
patients developed adverse events of Grade 2 or higher. The patientwith chest pain reported transient symptoms on the 3rd post-
operative day, blood pressure, heart rate, SpO2, and electrocardio-
gram were normal. The patient with subcutaneous hemorrhage
was one of 19 patients in whom a subcutaneous surgical drain was
placed. A 2 cm 3 cm hematomawas detected on ultrasonography
after removal of the drain on the 3rd postoperative day and enox-
aparin sodium was discontinued. There was no incidence of
epidural hematoma in the 133 patients in whom an epidural
catheter had been placed.
No patients developed clinical signs of DVT or PE. Among the
102 women who underwent venous ultrasonography, none had
thrombus before C/S; new thrombus was detected in four patients
(3.9%). All of the thrombi were detected in unilateral soleus veins (2
on the right and 2 on the left). In these four patients, possible
causes of thrombophilia, such as antithrombin III deﬁciency, pro-
tein C deﬁciency, protein S deﬁciency, and antiphospholipid syn-
drome, were excluded at a follow-up appointment 1 month or later
postpartum.
The factors associated with asymptomatic DVT were examined.
The only factor signiﬁcantly associated with asymptomatic DVT
was being overweight (BMI  25 kg/m2 before pregnancy; Table 2).
Factors that did not reach statistical signiﬁcance were advanced
maternal age  35 years (n ¼ 3), prolonged bed rest  48 hours
(n ¼ 3), and twin pregnancy (n ¼ 2).Discussion
In this study, no serious adverse events of Grade 2 or higher
were reported or detected. In the one patient reporting chest pain,
symptoms were transient, and heart rate, SpO2, and electrocar-
diogram remained normal. This woman did not undergo computed
tomography pulmonary angiography to exclude PE. Therefore,
nonlife threatening PE cannot be completely ruled out because
SpO2, blood pressure, and heart rate could be normal in a relatively
young and healthy woman with a small PE. In the patient with
subcutaneous hemorrhage, the hematoma was detected by ultra-
sonography after removal of the surgical drain, but no clinical signs
were evident. Whether the hematoma was related to administra-
tion of enoxaparin sodium, or placement or removal of the sub-
cutaneous drain is unknown. The study ﬁndings are broadly
comparable with other reports in which Japanese women received
enoxaparin sodium after C/S according to a similar protocol [11].
Table 2
Effect of potential risk factors on the incidence of deep vein thrombosis.
Parameters DVT nonDVT p
(n ¼ 4) (n ¼ 98)
Indications (clinical background)
Maternal age (y) 36.0 (34e41) 36.0 (22e49) 0.489
Body mass index 28.5 (22.9e29.4) 24.5 (19.2e43.6) 0.049
No. of patients with prolonged bed rest 3 (75.0) 47 (48.0) 0.290
No. of patients with twin pregnancy 2 (50.0) 31 (31.0) 0.433
Parameters related to cesarean section
No. of patients requiring emergency cesarean section 2 (50.0) 34 (34.6) 0.547
Duration of surgery (min) 56.5 (33e88) 62 (22e195) 0.476
Blood loss (mL) 1,045 (710e1817) 790 (272e2745) 0.375
Parameters related to administration of enoxaparin
Interval between cesarean section & enoxaparin administration (h) 30.5 (28e31) 31.0 (20e46) 0.476
Postoperative data
D-dimer levels (mg/mL)
Before cesarean section 2.2 (1.1e7.0) 3.0 (0.2e10.8) 0.622
Postoperative Day 1 11.6 (4.9e16.7) 7.0 (1.6e50.3) 0.141
Postoperative Day 3 3.3 (2.6e8.3) 2.0 (0.8e19.5) 0.129
Postoperative Day 6 3.6 (2.9e7.3) 2.0 (0.7e20.9) 0.077
Data are presented as n (%) or median (range).
DVT ¼ deep vein thrombosis.
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receiving thromboprophylaxis using unfractionated heparin or
LMWH after C/S. This study found that the incidence of asymp-
tomatic DVT among women at high risk of VTE was 3.9%. Two
previous studies reported that symptomatic DVT was detected in
0.04% and 0.5% of patients [6,16]. The patients in these two studies
were randomly selected populations in which thromboprophylaxis
was not administered. The incidence of DVT is likely to be affected
by the population studied, the thromboprophylaxis protocol used,
and the timing and method of ultrasound examination. Neverthe-
less, no cases of thrombophilia among the four women diagnosed
with asymptomatic DVT were detected by this study. In the 102
patients in whom no DVT was detected by ultrasonography before
C/S, all of the deep veins in the lower extremities, including the calf
muscle veins, were examined 6 days after C/S when the course of
enoxaparin had ﬁnished. In the four cases of asymptomatic DVT,
thrombus was only detected in unilateral soleus veins. The patho-
physiological signiﬁcance of soleus vein thrombosis is not fully
understood, because only 20% of calf muscle vein thromboses
propagate to the proximal veins, which carry a higher risk for PE
[17e19].
Our enoxaparin administration protocol was designed in
accordance with the standard indication in Japan, which states that
the ﬁrst dose should be given 24e36 hours after surgery. Devel-
opment of this guidance was informed using data from Japanese
patients who had undergone orthopedic surgery, after which pa-
tients may be immobile for some time. By contrast, women who
have undergone C/S are likely to be healthier, younger, and more
active than those who have undergone orthopedic surgery. Most
thrombi develop within 24 hours of C/S, and symptoms related to
VTE are likely to occur by the 3rd postoperative day [17,20].
Although there were no signiﬁcant differences in the interval be-
tween C/S and the administration of enoxaparin sodium in women
with and without DVT, future studies should focus on the optimum
time that administration of LMWH should commence.
In the current study, the only signiﬁcant risk factor associated
with DVT was being overweight. Whether being overweight itself
was a risk factor, or whether the dose of LMWH was not sufﬁcient
for the overweight patients' body mass is unclear. Logically, heavier
women should receive higher doses of enoxaparin sodium, but the
appropriate dose for body weight has not yet been determined.
Other risk factors, including advanced maternal age, prolonged bed
rest, and twin pregnancy, were not signiﬁcant, but study ﬁndingssuggest that patients with multiple risk factors were more likely to
develop asymptomatic DVT. According to the VTE prevention
guidelines in the United States [4] and the United Kingdom [21], but
not Japan [3], patients with multiple risk factors are good candi-
dates for prophylactic LMWH. In these cases, more frequent use of
LMWH may be considered and the efﬁcacy of such an approach
should also be established.
The incidence of VTE, including asymptomatic DVT that was
detected by ultrasonography in the low risk population after C/S
without thromboprophylaxis, was 0e0.8% in ﬁve previous reports
in which the sample sizes were small, ranging between 59 and 194
[16,20,22e24]. In three studies inwhich the number of participants
was less than 100, no DVTwas detected [22e24]. To date, no clinical
trials have evaluated the incidence of VTE, including asymptomatic
DVT, after C/S in the known at-risk population with thrombopro-
phylaxis using LMWH. Therefore, in this study, a sample size of >
100 was determined a priori. The limitations of this study are that
the sample size was relatively small and the study designwas not a
randomized control study.
This study shows the safety and efﬁcacy of enoxaparin for
thromboprophylaxis after C/S. However, four cases of asymptom-
atic DVT were reported. Further studies on the prevention of
asymptomatic DVT, a potential risk factor for clinical VTE, are
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